Matches in UGent Biblio for { <https://biblio.ugent.be/publication/412731#aggregation> ?p ?o. }
Showing items 1 to 39 of
39
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B337323.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2005".
- aggregation format "application/pdf".
- aggregation hasFormat 412731.bibtex.
- aggregation hasFormat 412731.csv.
- aggregation hasFormat 412731.dc.
- aggregation hasFormat 412731.didl.
- aggregation hasFormat 412731.doc.
- aggregation hasFormat 412731.json.
- aggregation hasFormat 412731.mets.
- aggregation hasFormat 412731.mods.
- aggregation hasFormat 412731.rdf.
- aggregation hasFormat 412731.ris.
- aggregation hasFormat 412731.txt.
- aggregation hasFormat 412731.xls.
- aggregation hasFormat 412731.yaml.
- aggregation isPartOf urn:issn:1084-9785.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Radiolabeled lipiodol therapy for hepatocellular carcinoma in patients awaiting liver transplantation: pathology of the explant livers and clinical outcome".
- aggregation abstract "Background: Liver transplantation has become an important curative treatment option for hepatocellular carcinoma (HCC). Criteria for transplantation are strict and, therefore, it is crucial that patients awaiting transplantation do not suffer disease progression. One of the therapeutic options to achieve disease stabilization is neoadjuvant radiolabeled lipiodol treatment. This study aimed to document the dropout rate on the waiting list, the pathological findings on the explant livers, and the long-term outcome of patients treated. with radionuclide therapy while awaiting transplantation. Methods: Patients eligible for transplantation were treated with 2.1 GBq I-131-lipiodol or 4.1 GBq Re-188-HDD/lipiodol by transfemoral catheterization of the hepatic arteries. Tumor necrosis was assessed in the explant livers and,follow-up data, such as dropout from the waiting list, recurrence, and survival following transplantation were retrospectively documented. Results: In 5 of 22 explants, necrosis exceeded 90%. Two patients died while, on the waiting list (10%) and 4 of 20 transplanted patients (20%) suffered recurrent disease. The overall recurrence-free survival was 19.7 months (range, 1.75-56), with a mean follow-up of 20. 1 months. Conclusion: Our data support the evaluation on larger patient numbers to confirin the benefit of radiolabeled lipiodol in candidates for liver transplantation who are suffering from HCC.".
- aggregation authorList BK633640.
- aggregation endPage "214".
- aggregation issue "2".
- aggregation startPage "209".
- aggregation volume "20".
- aggregation aggregates 848522.
- aggregation isDescribedBy 412731.
- aggregation similarTo cbr.2005.20.209.
- aggregation similarTo LU-412731.